World's Best Scientists 2026 revealed!
Kwang Hyub Han

Kwang Hyub Han

Award Badge
Medicine
Korea
2023

D-Index & Metrics

Medicine

D-Index
101
Citations
51572
World Ranking
7827
National Ranking
19

Research.com Recognitions

  • 2023 - Research.com Medicine in Korea Leader Award
  • 2022 - Research.com Medicine in Korea Leader Award

Overview

Kwang Hyub Han is affiliated with Yonsei University in South Korea. Their research primarily spans the field of Medicine, with significant contributions to subfields including Epidemiology, Hepatology, Surgery, Pulmonary and Respiratory Medicine, and Oncology.

Their work focuses on various main topics such as Liver Disease Diagnosis and Treatment, Hepatocellular Carcinoma Treatment and Prognosis, Hepatitis B Virus Studies, Hepatitis C Virus Research, Liver Disease and Transplantation, Coronary Interventions and Diagnostics, and Cancer Mechanisms and Therapy.

Frequent publication venues include:

  • Journal of Hepatology
  • Gut and Liver
  • The American Journal of Gastroenterology
  • Clinical and Molecular Hepatology
  • International Journal of Radiation Oncology*Biology*Physics

Kwang Hyub Han has collaborated frequently with several co-authors, including:

  • Jun Yong Park
  • Sang Hoon Ahn
  • Seung Up Kim
  • Do Young Kim
  • Beom Kyung Kim

Notable recent publications include:

  • "A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements," 2020, Liver Cancer
  • "Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease," 2020, Circulation
  • "Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk," 2020, The American Journal of Gastroenterology
  • "A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma," 2020, Journal of Hepatology
  • "Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase," 2020, Alimentary Pharmacology & Therapeutics

Best Publications

  • Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

    Masatoshi Kudo;Richard S. Finn;Shukui Qin;Kwang Hyub Han

  • A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B

    Ting Tsung Chang;Robert G. Gish;Robert De Man;Adrian Gadano

  • Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

    Masao Omata;Ann Lii Cheng;Norihiro Kokudo;Masatoshi Kudo

  • Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

    Yun-Fan Liaw;Nancy H. L. Leung;Jia-Horng Kao;Teerha Piratvisuth

  • Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.

    Yun Fan Liaw;Jia Horng Kao;Teerha Piratvisuth;Henry Lik Yuen Chan

  • Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B

    Ting Tsung Chang;Yun Fan Liaw;Shun Sheng Wu;Eugene Schiff

  • Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

    Masao Omata;Laurentius A. Lesmana;Ryosuke Tateishi;Pei Jer Chen

  • Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

    Jordi Bruix;Tadatoshi Takayama;Vincenzo Mazzaferro;Gar Yang Chau

  • Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

    Thomas Karlas;David Petroff;Magali Sasso;Jian Gao Fan

  • Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

    Philip J. Johnson;Shukui Qin;Joong Won Park;Ronnie T.P. Poon

  • Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study

    Hyeon Chang Kim;Chung Mo Nam;Sun Ha Jee;Kwang Hyub Han

  • Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score

    Hwai I. Yang;Hwai I. Yang;Man Fung Yuen;Henry Lik Yuen Chan;Kwang Hyub Han

  • A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

    William Sievert;Ibrahim Altraif;Homie A. Razavi;Ayman Abdo

  • The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.

    A. Sibley;Kwang Hyub Han;A. Abourached;L. A. Lesmana

  • Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

    Robert G. Gish;Anna S. Lok;Ting Tsung Chang;Robert A. de Man

  • Risk assessment of hepatitis B virus–related hepatocellular carcinoma development using liver stiffness measurement (FibroScan)

    Kyu Sik Jung;Seung Up Kim;Sang Hoon Ahn;Young Nyun Park

  • Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.

    Shiv K. Sarin;Manoj Kumar;Mohammed Eslam;Jacob George

  • Performance of Transient Elastography for the Staging of Liver Fibrosis in Patients with Chronic Hepatitis B: A Meta-Analysis

    Young Eun Chon;Eun Hee Choi;Ki Jun Song;Jun Yong Park

  • Dose-response relationship in local radiotherapy for hepatocellular carcinoma

    Hee Chul Park;Jinsil Seong;Kwang Hyub Han;Chae Yoon Chon

  • NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome

    Stefan Zeuzem;Masashi Mizokami;Stephen Pianko;Alessandra Mangia

Frequent Co-Authors

Sang Hoon Ahn
Sang Hoon Ahn Yonsei University
Young Nyun Park
Young Nyun Park Yonsei University
Masatoshi Kudo
Masatoshi Kudo Kindai University
Young-Suk Lim
Young-Suk Lim University of Ulsan
Ann-Lii Cheng
Ann-Lii Cheng National Taiwan University
Myeong-Jin Kim
Myeong-Jin Kim Yonsei University
Jia-Horng Kao
Jia-Horng Kao National Taiwan University
Ching-Lung Lai
Ching-Lung Lai University of Hong Kong
Pei-Jer Chen
Pei-Jer Chen National Taiwan University
Henry Lik-Yuen Chan
Henry Lik-Yuen Chan Chinese University of Hong Kong

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative or complementary education options can open up diverse career pathways in healthcare. For those interested in the management side of healthcare, pursuing a health administration degree online offers flexibility and can lead to roles in hospital administration or healthcare management.

If you already have a bachelor’s degree, you might consider advancing with one of the cheapest mha programs online. These programs develop leadership and strategic skills, preparing you for upper management positions within healthcare settings.

Those aiming for clinical expertise can look at terminal degrees such as the Doctor of Nursing Practice (DNP). There are several least expensive dnp programs available online, which are ideal for nurses seeking to advance their clinical practice while balancing work and studies.

Pharmacists and aspiring students may benefit from the convenience of online pharm d programs. These programs can make it easier to pursue advanced pharmacy education, leading to expanded roles in patient care and pharmacy leadership.

Best Scientists Citing Kwang Hyub Han

Trending Scientists

Recently Published Articles